Patents by Inventor JON LEIGH RUNDLE

JON LEIGH RUNDLE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11466324
    Abstract: The present invention provides the use of lipocalin 2 (LCN2) as a biomarker for IL-17 mediated diseases and for monitoring the response of a patient to anti-IL-17 therapy.
    Type: Grant
    Filed: January 15, 2019
    Date of Patent: October 11, 2022
    Assignee: UCB BIOPHARMA SRL
    Inventors: Adam Samuel Platt, Stephen Edward Rapecki, Mara Fortunato, David Robert Rainey, Jon Leigh Rundle, Paul Alfred Smith, Gillian Fairfull Watt
  • Patent number: 10208349
    Abstract: The present invention provides the use of lipocalin 2 (LCN2) as a biomarker for IL-17 mediated diseases and for monitoring the response of a patient to anti-IL-17 therapy.
    Type: Grant
    Filed: November 19, 2013
    Date of Patent: February 19, 2019
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Adam Samuel Platt, Stephen Edward Rapecki, Mara Fortunato, David Robert Rainey, Jon Leigh Rundle, Paul Alfred Smith, Gillian Sairfull Watt
  • Publication number: 20140080134
    Abstract: The present invention provides the use of lipocalin 2 (LCN2) as a biomarker for IL-17 mediated diseases and for monitoring the response of a patient to anti-IL-17 therapy.
    Type: Application
    Filed: November 19, 2013
    Publication date: March 20, 2014
    Applicant: UCB PHARMA S.A.
    Inventors: ADAM SAMUEL PLATT, STEPHEN EDWARD RAPECKI, MARA FORTUNATO, DAVID ROBERT RAINEY, JON LEIGH RUNDLE, PAUL ALFRED SMITH, GILLIAN SAIRFULL WATT